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Summary The sensitivity of human breast and lung cancer cell lines to TGF-a-PE40, a novel chimeric
recombinant cytotoxin composed of two independent domains, (i) TGF-x and (ii) a 40 kDa segment of the
Pseudomonas exotoxin protein, PE-40, was investigated. Toxicity varied widely, correlated with epidermal
growth factor receptor (EGFR) levels (P = 0.01) and was greatly reduced by EGF, indicating that binding of
TGF-a-PE40 to EGFR is important in mediating toxicity. Cell lines expressing low EGFR levels were most
highly protected by EGF, indicating that normal (low EGFR-expressing) tissue may be selectively protected by
EGF in vivo. P-glycoprotein did not confer resistance to TGF-a-PE40, and toxicity was unaffected by
multidrug resistance-modulating agents (cyclosporin A, tamoxifen, verapamil), indicating a role for TGF-.x
PE40 in the clinical management of drug-resistant tumours.
Expression of epidermal growth factor receptors (EGFRs)
has been detected in several malignant tumour types, includ-
ing breast (Nicholson et al., 1991), ovarian (Kohler et al.,
1992), lung and glial tumours (Chaffenet et al., 1992; Fleming
et al., 1992). EGFR overexpression correlates with poor cel-
lular differentiation (Bolla et al., 1992), which is in turn a
marker for poor prognosis in lymph node-negative breast
cancer (Nicholson et al., 1991), non-small-cell lung cancer
(Veale et al., 1993) and superficial bladder cancer (Smith et
al., 1989; Neal et al., 1990). In breast cancer cells, increased
expression correlates with reduced oestrogen receptor (ER)
levels (Bilous et al., 1992), and such an increase is associated
with tamoxifen resistance (Nicholson et al., 1989). Over-
expression of EGFR is also associated with the multidrug
resistance (MDR) phenotype (Shin et al., 1991). There is
therefore potential to exploit the difference between EGFR
expression in normal and MDR-positive, malignant cells in
order to target treatment to tumours which may respond
poorly to chemotherapy (Harris, 1990).
We have assessed the toxicity of a chimeric cytotoxin
composed of two independent domains: (i) transforming
growth factor a (TGF-o) and (ii) PE40, a 40 kDa segment of
Pseudomonas exotoxin (PE). The toxicity of multidomain PE
is abolished when the cell targeting moiety is removed to
yield PE40, which can neither bind to nor enter cells (Pastan
& FitzGerald, 1989). Conjugating TGF-a to PE40 restores
cell-binding activity, allowing selective entry ofTGF-oc-PE40
(TP40) into EGFR-positive cells. Normal tissue expressing
low levels of EGFR may therefore be less susceptible to
toxicity. We have tested this hypothesis by determining the
toxicity of TP40 to human breast cancer and lung cancer cell
lines expressing different levels of EGFR. P-glycoprotein
(Pgp)-positive cell lines were also included in the study to
determine whether MDR confers cross-resistance to the
chimeric toxin. The effects of the MDR modifiers tamoxifen
(Ramu et al., 1984; Kirk et al., 1993a,b), verapamil (Tsuruo
et al., 1981) and cyclosporin A (Twentyman et al., 1987) on
TP40 toxicity were also investigated; previous studies have
suggested that verapamil may enhance the toxicity of
chimeric toxins by altering PE40 processing in endosomes
(Lyall et al., 1987; Jaffrezou & Laurent, 1993).
Materials and methods
Cell lines and tissue culture
The panel of cell lines used comprised eight human breast
cancer, four small-cell lung cancer (SCLC) and nine non-
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small-cell lung cancer (NSCLC) cell lines (Table I), which
express EGFR at different levels. These included the breast
cancer cell line MDA-468, which greatly overexpresses
EGFR (Filmus et al., 1985), and non-adherent SCLC cell
lines, which do not express EGFR. The cell lines varied in
sensitivity to cytotoxic drugs and included two MDR-positive
cell lines expressing Pgp: (i) the mdrl transfectant, S1/1.1,
which has mdrl levels at least 100-fold higher than its wild-
type parental cell line, SI (Baas et al., 1990; F. Baas, per-
sonal communication); and (ii) MCF-7Adr (Batist et al., 1986),
derived from the human breast cancer cell line MCF-7 (Soule
et al., 1973) by chronic exposure to adriamycin. Two strains
of MCF-7 cells were used: an early-passage strain (MCF-7EP;
passage 50-60) and a late-passage strain (MCF-7LP; passage
>300) in order to monitor changes in receptor status and
drug sensitivity during long-term growth in vitro. S1 and
S1/1.l cells were kindly provided by F. Baas (University of
Amsterdam, The Netherlands), other lung cancer cell lines by
A.F. Gazdar (NCI Navy Medical Oncology Branch, Bethesda,
MD, USA) and MCF-7Adr breast cancer cell lines by K.
Cowan (NCI Clinical Pharmacology Branch).
All cell lines were maintained as monolayer cultures in
Ham's F12 medium (S1 and Si/1.1) or RPMI-1640 medium
(all other cell lines), each supplemented with 10% fetal calf
serum (FCS) and 2 mM glutamine. Cultures were grown in
5% carbon dioxide under 100% humidity at 37°C and main-
tained in exponential growth phase by passaging twice
weekly. All cell lines were regularly shown to be Mycoplasma
free, and are listed in Table I.
Drugs
TP40 (provided by David Heimbrook, Merck Sharpe &
Dohme Research Laboratories, West Point, PA, USA), was
diluted to 2 or 20ILM in phosphate-buffered solution (PBS),
divided into aliquots and stored at - 20°C. Tamoxifen, pro-
vided by ICI Pharmaceuticals (Macclesfield, UK), was
prepared as a 50 mM stock solution in ethanol and stored at
4C. Verapamil (Sigma, Dorset, UK) and cyclosporin A
(Sandoz) were dissolved in dimethylsulphoxide (DMSO) to
20 mM and diluted in PBS as appropriate. EGF (tissue cul-
ture grade, from Sigma) was dissolved in PBS to 10 jgml-',
filtered (0.22pm), aliquoted and stored at - 20C. Tamoxi-
fen, verapamil and cyclosporin A were added to cells at their
maximum non-toxic concentration (MNC), defined as the
maximum concentration tested which reduced control cell
optical density by less than 5% after 4 days' growth. Organic
solvent levels did not exceed 0.1% by volume of the cell
suspension, a concentration of vehicle demonstrated not to
affect cell growth.
Br. J. Cancer (1994), 69, 988-994 (D Macmillan Press Ltd., 1994TGF-a-PE40 AND EGF 989
Table I Characteristics of cell lines. Oestrogen and EGF receptor levels were
determined from cytosol and membrane fractions respectively, derived from the
same sample of cells. TP40 IC50 values were determined by growing cells
continuously for 4 days in the presence and absence of TP40 at a range of
concentrations. Cell viability was assessed using a semiautomated MTT assay.
TP40 ICm values are mean results from four separate determinations ±s.e.m.
Cell type Cell line ERta EGFR
a TP40 IC50 (pM)
Breast cancer MCF-7EP 92 0 38 ± 4
MCF-7LP 59 7 41 ± 8
MCF-7Adr <5 405 152 ± 11
MDA-231 <5 108 227 25
MDA-361 60 5 649 9
MDA-468 <5 4,480 22± 3
SKBr3 <5 674 116 6
T47D 47 52 74± 15
ZR75 14 120 132 39
SCLC NCI-H 249 <5 0 180,000 6,300
NCI-N 417 <5 32 2,360+ 390
NCI-H 526 10 0 117,000+9,900
NCI-H 841 <5 723 43 4
NSCLC NCI-H 226 <5 632 46 ± 12
NCI-H 322 <5 575 19 3
NCI-H 358 <5 184 36 9
NCI-H 460 <5 0 193 24
NCI-H 522 <5 10 35,100+ 1,200
NCI-H 647 <5 70 126 17
Si <5 720 133±16
S1/1.1 <5 470 145± 15
A549 <5 566 14 2
'Cellular EGFR and ER levels are expressed in units of ligand bound
(fmol mg-' protein).
Cytotoxicity assays
Exponentially growing cells were trypsinised, centrifuged and
resuspended in fresh medium (10% FCS, 2 mM glutamine) at
the appropriate cell density. Cell suspension (180 1tl) was
aliquoted into 96 well microtitre plates at a seeding density
previously demonstrated to allow exponential growth for 4
days. Modifiers, drug (at eight different concentrations) and/
or vehicle (10pl) were added in quadruplicate at appropriate
concentrations. Cells were incubated continuously with drug
and/or modifier at 37°C (5% carbon dioxide, 100%
humidity) for 4 days. Cytotoxicity was determined using the
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay (Mosmann, 1983; Carmichael et al., 1987).
Aliquots of MTT (50 tLI, 2 mgml-') were dispensed into all
wells and the cells incubated for a further 4 h. Plates were
inverted to discard medium and formazan crystals were
solubilised in 100yl of DMSO with 25 tlI of glycine buffer
(0.1 M glycine/0.1 M sodium chloride, pH 10.5; Plumb et al.,
1989). Plates were agitated for 5 min, and optical densities
determined immediately at 540 nm using a Titertek Multis-
kan Plus MKII ELISA plate reader. Data were stored and
processed on a Macintosh SE/30 microcomputer.
Receptor assays
Cells ( 108) in exponential growth phase, harvested by tryp-
sinisation and washed three times with PBS, were
resuspended in 4 ml of ice-cold homogenisation buffer
(20 mM HEPES, 1.5 mM EDTA, 0.5 mM PMSF, 1 mM ben-
zamidine, 10 ng ml-' ovomucoid, pH 7.4) and allowed to
stand on ice for 30 min. Cells were lysed by homogenisation
(30 strokes in a glass-glass homogeniser) on ice, centrifuged
(3,000 r.p.m., 10 min, 4'C) to pellet nuclei and unbroken
cells, and the resulting supernatants centrifuged at 100,000g
for 45 min at 4'C. Supernatants (cytosolic extracts) were
removed and supplemented with ice-cold dithiothreitol
(200 mM) to a final concentration of 2 mM. Membrane pellets
were rinsed twice with 0.5 ml of ice-cold membrane resuspen-
sion buffer (50 mM Tris, 150 mM sodium chloride, pH 7.4)
then resuspended by gentle pipetting in 1.5 ml of membrane
resuspension buffer. Cytosolic ER levels were determined
using an Abbott ER-EIA Monoclonal kit (Abbott Labora-
tories, North Chicago, USA) by Atilla Turkes (Tenovus
Insitute for Cancer Research, University of Wales College of
Medicine, Cardiff, UK). Membrane EGFR levels were deter-
mined by ligand binding using ['25I]EGF, as previously de-
scribed (Nicholson et al., 1988). ER and EGFR receptor
levels are expressed in terms of ligand bound per unit
cytosolic or membrane protein (fmol mg-') respectively, and
the limit of sensitivity of the EGFR assay was 1 fmol mg-'
of membrane protein.
Data analysis
Dose-response data were fitted to a four parameter equation
using DeltaSoft ELISA Analysis software (BioMetallics,
Princeton, NJ, USA). IC_0 values (concentration of drug
causing a 50% reduction in control cell optical density) were
determined by interpolating into the equation a value 50% of
control cell optical density. ICm values are presented as the
mean from at least four separate experiments ± the standard
error of the mean (s.e.m.). Modification of drug toxicity is
expressed as a modification factor (MF), calculated by
dividing the IC50 value determined in the presence ofmodifier
by that measured in its absence. MF values > 1 indicate
protection from drug toxicity and values <1 enhancement of
drug toxicity, while a value of 1 indicates no modification.
TP40 ICo values determined in the presence and absence of
modifiers were compared using Student's paired two-tail t-
test. Correlations between EGFR and ER levels, and
between cellular EGFR levels and sensitivity to TP40, were
analysed by calculating Kendall's coefficient of rank correl-
tion (X); significance levels (P, one-tailed test) determined
from Xr are quoted in the text.
Results
EGFR and ER levels
EGFR levels ranged from 0 to 4,480 fmol mg-' (Table I).
For breast cancer cell lines, an inverse relationship (P = 0.01)990 J. KIRK et al.
was observed between EGFR and ER levels (Figure 1).
MCF-7LP cells expressed lower ER levels and higher EGFR
levels than MCF-7EP, although both cell lines were highly ER
positive. For SCLC cell lines, anchorage-independent NCI-H
249 and NCI-H 526 cells expressed no detectable EGFR,
adherent NCI-H 841 cells expressed high EGFR levels (723
fmol mg-') and semiadherent NCI-N 417 cells expressed
intermediate levels (32 fmol mg-'), indicating a correlation
between loss of anchorage independence and EGFR expres-
sion. NSCLC cell lines, with the exception of NCI-H 460 and
NCI-H 522 cells, expressed high levels of EGFR.
Effects ofEGF on growth oflung and breast cancer cell lines
Marked variability was observed between the effects of EGF
(0.1-300 ngml-') on the growth of breast (Figure 2a) and
lung cancer cell lines (Figure 2b). Growth of highly EGFR-
positive MDA-468 cells was inhibited 54% by 10 ngml-'
EGF, while 100 ngml-' EGF stimulated MCF-7Adr cell
growth by 22%. Stimulation of SI, S1/1.1 (data not shown)
and NCI-H 226 cell growth occurred at 30-100ngml-'
EGF. These cell lines expressed relatively high levels of
EGFR (-350-500 fmol mg-'), however NCI-H 322 and
NCI-H 841, which also expressed high levels (575 and
723 fmol mg-' respectively), were unaffected by EGF treat-
ment. No effect on other lung cancer cell lines that expressed
low levels of EGFR (data not shown) was observed.
TP40 toxicity
TP40 was toxic to all cell lines tested, with a 13,000-fold
range in IC50 values observed (Table I). NCI-H 249, NCI-H
522 and NCI-H 526 cells, which expressed low levels of
EGFR (0-10 fmol mg-'), were most resistant to TP40
(IC50 = 35,000-180,000 pM), while MDA-468 cells, which
expressed the highest level detected (4,480 fmol mg-'), were
highly sensitive (IC50 = 22 pM). Similarly, NCI-H 226, NCI-H
322, NCI-H 841 and A549 cells, which were also highly
EGFR positive (566-723 fmol mg-'), were very sensitive to
TP40, with IC50 values of 14-46 pM. This trend is illustrated
in Figure 3, which shows TP40 IC50 values plotted as a
function of EGFR levels for the panel of breast and lung
cancer cell lines. A correlation (P = 0.01) was observed,
indicating an inverse relationship between TP40 IC50 values
and EGFR levels. This correlation was weakened by results
obtained using NCI-H 460 and (early and late passage)
MCF-7 cells which were sensitive to TP40 but expressed very
low levels of EGFR (Table I), and masking these values gave
a stronger correlation (P = 0.005).
Lung and breast cancer cell lines were also analysed
separately, as these are two histologically and biologically
distinct groups of cells. EGFR levels were related to TP40
sensitivity for the 13 lung cancer cell lines alone (P = 0.005).
Weaker correlations were observed when this sample was
divided into NSCLC (P = 0.05) and SCLC cell lines
(P = 0.05), presumably because of the small sample number
in each subgroup. No correlation was observed for breast
cancer cell lines, even when values for MCF-7 cells were
omitted.
S1 cells and their mdrl-transfected subline, S1/1.1, were
equally sensitive to TP40, indicating that Pgp does not confer
resistance to this toxin. MCF-7AdF cells were relatively sen-
sitive to TP40 when compared with other cell lines tested, but
more resistant than MCF-7 cells. However, this result prob-
ably reflects the unusual sensitivity of MCF-7 cells to
TP40.
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Figure 1 Correlation between ER levels and EGFR levels for
breast cancer cell lines. Values were determined from cytosolic
and membrane fractions, respectively, prepared from the same
sample of cells.
Figure 2 Effects of EGF on growth of (a) breast cancer and (b)
lung cancer cell lines. a, MCF-7 (A), MCF-7Adr (0), MDA-231
(0), MDA-468 (A). b, SI (A), NCI-H 226 (0), NCI-H 322
(0), NCI-H 841 (A). Results are from one representative
experiment± s.d. calculated from four replicates. Where not
shown, error bars fall within the area of plot symbols.
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Figure 3 TP40 ICu values plotted as a function of EGFR levels
for (a) breast (0) and (b) non-small cell (A) and small-cell (A)
lung cancer cell lines. TP40 ICu values are means ± s.e.m. deter-
mined from at least four identical experiments.
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Figure 4 Effect of 0 (A), 1O (0), 100 (A) and 500 ngml-' (A)
EGF on TP40 toxicity to (a) SI and (b) Sl/l.1 cells. Results are
from one representative experiment ± s.d. calculated from four
replicates. Where not shown, error bars fall within the area of
plot symbols.
Effects ofmodifiers on TP40 toxicity
Figure 4a and b shows the effects of 0, 10, 100 and
500 ng ml-' .EGF on TP40 toxicity to SI and Sl/1.1 cells.
EGF caused a concentration-dependent rightward shift in the
dose-response curves, indicating antagonism of TP40 tox-
icity. This protective effect was observed with all cell lines
tested, and IC50 values for TP40 determined in the absence
and presence of the highest concentration of EGF used
(500 ng ml- ') are listed in Table II. TP40 toxicity was
reduced 81- (NCI-H 226) to 240-fold (SI/1.1). The degree of
protection (MF) at 10 ng ml-' (Figure 5a) and 100 ng ml-'
EGF (Figure Sb) was plotted as a function of EGFR levels
for eight lung and breast cancer cell lines, and strong correla-
tions (r = - 0.8 and - 0.9 respectively) were observed at each
concentration, while the degree of protection at 500 ng ml-'
EGF did not correlate with EGFR levels (r = 0.01, data not
shown). At IO and 100 ng ml-' EGF, therefore, cell lines
expressing low levels (<50 fmol mg-1) of EGFR were most
highly protected from TP40 toxicity.
The MDR-modifying agents tamoxifen, verapamil and
cyclosporin A did not alter TP40 toxicity to any cell line
tested (Table II), although verapamil has previously been
shown to enhance toxicity of a different PE conjugate, EGF-
PE, to human KB cells (Lyall et al., 1987; Jaffrezou &
Laurent, 1993).
Discussion
An inverse relationship was observed between ER and
EGFR levels for the breast cancer cell lines, similar to results
on human tumour biopsies previously published (Sainsbury
et al., 1985; Harris & Nicholson, 1988; Bilous et al., 1992;
Bolla et al., 1992). EGFR-positive cells may have a growth
advantage over hormone-dependent, EGFR-negative cells
and outgrow ER-positive cells both in vitro and in vivo. This
effect is apparent with wild-type MCF-7 cells, early-passage
cells being EGFR-negative and highly ER-positive, while
later passage cells express low levels of EGFR and reduced
levels of ER. SCLC cell lines generally grow in an anchorage-
independent manner and do not express EGFR, however loss
of the non-adherent phenotype may occur during continuous
growth in vitro. Such loss was correlated in our panel of cell
lines with increased expression of EGFR. Gamou et al.
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Table II Effects of tamoxifen, cyclosporin A, verapamil and EGF on TP40 toxicity to human breast
and lung cancer cell lines. Cells were exposed to TP40 and/or modifiers continuously for 4 days. Cell
viability was assessed using a semiautomated MTT assay. Results are mean values from at least five
identical experiments ± s.e.m.
TP40 IC50 value (pM)
Cell line + PBS + EG? + Tamoxifenb + CsAc + Verapamit
MCF-7EP 38 4 4,900 ± 1,300* 32 ± 3 38 8 34 6
MF - 130 Id
MCF-7Adr 152 11 20,900 ± 800*** 123 21 192 34 170 31
MF - 140 1 1 1
MDA-468 22 4 - 27 1 29 5 22 9
MF _ _ 1 1 1
S1 133 16 25,600+ 3,600** 135 17 132 27 142 19
MF - 192 1 1 1
Sl/1.1 145 16 34,400 + 3,900** 144 13 121 23 153 38
MF - 240 1 1 1
NCI-H1 226 46 12 3,700 ± 900* 47 7 44 8 41 11
MF - 81 1 1 1
'EGF was added to cells at 500 ngml-1. bTamoxifen was added to cells at 1 t4M (MCF-7 cells) or
1OtLM (remaining cell lines). cCyclosporin A (CsA) and verapamil were added to cells at 5 AM. dWhere
MF= 1, P =0.05-1. *P =0.01-0.05, **P =0.001 -0.01, ***P =0.0001-0.001.
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Figure 5 Modification of TP40 toxicity by (a) 10 and (b)
lOOngml-' EGF as a function of EGFR levels. Modulation of
TP40 toxicity is expressed as a modification factor (ratio of TP40
IC50 values determined in the presence and absence of EGF).
Results are mean values calculated from five identical experi-
ments ± s.e.m.
(1990) also observed increased levels of EGFR and loss of
anchorage independence in SCLC variants isolated from cul-
tures treated either with a demethylating agent (5-azacyti-
dine) or with a tumour-promoting agent (12-O-tetradecanoyl-
phorbol-13-acetate).
EGF stimulated growth of NCI-H 226, SI, Sl/1.1 and
MCF-7Adr cells, all of which expressed high levels of EGFR
(350-630 fmol mg-'). However, other cell lines which bound
similar levels of EGF were unaffected by EGF. By contrast,
MDA-468 cells, which expressed the highest EGFR levels
detected, were growth inhibited by EGF. Such inhibition has
been described by Filmus et al. (1985), and also demon-
strated with the highly EGFR-positive cell line, A431 (Gill &
Lazar, 1981). Kaplan et al. (1990), working with MDA-468
cells, have suggested that inhibition is an artefact of in vitro
systems; EGF strongly stimulates glucose metabolism in
highly EGFR-positive cells, thereby depleting the medium of
this sugar and leading to cell death through glucose starva-
tion.
We have assessed TP40 toxicity to a panel of cell lines,
which displayed a 13,000-fold range in sensitivity. Cell lines
most resistant to TP40 expressed little or no EGFR, while
those most sensitive generally expressed high levels of EGFR.
This correlation between EGFR expression and TP40 sen-
sitivity for cells which are highly resistant or highly sensitive
to TP40 supports the hypothesis that TP40 enters cells via
binding of the TGF-a moiety to EGFR. Additional evidence
is provided by the dose-dependent protection from toxicity
observed in the presence of EGF. EGF may protect cells
from TP40 toxicity either directly, through competition for
binding to EGFR, and/or by down-regulating EGFR expres-
sion. At 10 and 100 ng ml-' EGF, cellular expression of
EGFR correlated inversely with the degree of protection
from toxicity, indicating that cell lines expressing low levels
of EGFR were most highly protected. For cells expressing
little EGFR, these concentrations of EGF apparently
reduced binding of TP40 to levels insufficient to cause toxi-
city. Higher levels of EGF would presumably be required to
prevent binding of TP40 to cells with high EGFR levels.
Normal tissue EGFR expression is 5-50 fmol mg' in non-
squamous tissues (Ozawa et al., 1988); EGF may therefore
selectively protect such tissues from the effects of TP40 in
vivo, leaving highly EGFR-positive tumour cells relatively
more sensitive. Potential therefore exists for further enhanc-
ing the therapeutic ratio.
The correlation between TP40 sensitivity and EGFR levels
did not apply to all cell lines; for example, NCI-H 460 and
MCF-7 (both early and late passage) cells were sensitive to
TP40 but expressed low levels of EGFR. NCI-H 460 cells
were, however, exquisitely sensitive to a wide range of
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cytotoxic drugs (e.g. adriamycin, AMSA, cisplatin, vinblas-
tine and VP16; S. Houlbrook, unpublished data), yet were
more resistant to TP40 than 14 of the 21 cell lines included in
this study. NCI-H 460 cells could therefore be considered
relatively resistant to TP40, when the extreme sensitivity to
chemotherapeutic agents is taken into consideration. The
inability to perfectly correlate EGFR levels with TP40 IC5o
values indicates that sensitivity to TP40 is not related solely
to the ability of the toxin to enter cells, although this may be
the predominant factor for cell lines with very high or very
low EGFR levels. Sensitivity to TP40 could occur via multi-
ple mechanisms, of which enhanced transport into the cell
(via EGFR) is only one. After binding to the cell membrane,
TP40 is internalised within endosomes, where in order to be
released into the cytosol it must first be proteolytically pro-
cessed to a 37 kDa fragment (PE37; Theuer et al., 1992).
Once in the cytosol, the catalytic domain of the toxin ADP-
ribosylates elongation factor 2, thereby inhibiting protein
synthesis. Theuer et al. (1992, 1993) found a TGF-o-PE37
conjugate to much more toxic than a derivative containing
full-length PE, indicating that proteolytic processing is not
100% efficient, and may be rate limiting. Processing rates and
efficiency may vary between different cell lines, perhaps
explaining different sensitivities to TP40 of cell lines with
similar EGFR levels.
Although TP40 was less toxic to Pgp-positive MCF-7Adr
cells than to wild-type MCF-7 cells, SI and Si/1.1 cells were
equally sensitive to TP40, and toxicity was not altered by the
MDR modulators tamoxifen, cyclosporin A or verapamil. It
is therefore unlikely that Pgp confers resistance to TP40, and
this toxin may be useful in the treatment of drug-resistant
tumours. Lyall et al. (1987) found that verapamil enhanced
toxicity of another PE conjugate, EGF-PE, to human KB
cells, and indeed many MDR modulators have also been
shown to enhance toxicity of ligand-toxin conjugates
(Jaffrezou & Laurent, 1993). Verapamil may sensitise cells to
PE conjugates by altering the pH within endosomes, thereby
enhancing translocation of the toxin to the cytosol (Lyall et
al., 1987). However, Jaffrezou and Laurent (1993) suggest
that a common mechanism, such as altered lipid metabolism,
may account for enhanced toxicity of both ligand-toxin
conjugates and drugs associated with MDR. Such sensitisa-
tion was not observed in the present study, indicating that
this effect may be specific either to the cell type or to the PE
conjugate used.
In conclusion, the recombinant cytotoxic protein TP40 was
highly toxic to EGFR-positive cells at picomolar concentra-
tions, while EGFR-negative cell lines tended to be more
resistant. Tumour cells refractory to conventional
chemotherapy frequently overexpress EGFR (Smith et al.,
1989; Nicholson et al., 1991) and may therefore be sensitive
to treatment with TP40. Low EGFR-expressing cells were
selectively protected from TP40 toxicity by EGF
(10-100 ng ml ), and EGF may have a role in combination
with TP40 to target highly EGFR-positive tumours in vivo.
Expression of Pgp was not associated with resistance to
TP40, which may also be effective in the treatment of MDR-
positive tumours.
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Abbreviations: EGF, epidermal growth factor; EGFR, epidermal
growth factor receptor; ER, oestrogen receptor; FCS, fetal calf
serum; MDR, multidrug resistance; PE, Pseudomonas exotoxin;
PE40, 40 kDa unit of Pseudomonas exotoxin; Pgp, P-glycoprotein;
TGF-ax, transforming growth factor a; TP40, TGF-a-PE40.
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